Global Progressive Supranuclear Palsy Therapeutics Market 2019-2023
SKU ID : TNV-14253028 | Publishing Date : 08-May-2019 | No. of pages : 124
Detailed TOC of Global Progressive Supranuclear Palsy Therapeutics Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: PIPELINE
PART 07: MARKET SEGMENTATION BY PRODUCT
Market segmentation by product
Comparison by product
Dopamine - Market size and forecast 2018-2023
Anticholinergic agents - Market size and forecast 2018-2023
Tricyclic antidepressants - Market size and forecast 2018-2023
Others - Market size and forecast 2018-2023
Market opportunity by product
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 12: MARKET TRENDS
PART 13: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 14: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
AbbVie Inc.
Acorda Therapeutics Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Merck & Co. Inc.
PART 15: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Global progressive supranuclear palsy therapeutics market pipeline: Overview
Exhibit 18: Global progressive supranuclear palsy therapeutics market pipeline: Snapshot
Exhibit 19: Product - Market share 2018-2023 (%)
Exhibit 20: Comparison by product
Exhibit 21: Dopamine - Market size and forecast 2018-2023 ($ millions)
Exhibit 22: Dopamine - Year-over-year growth 2019-2023 (%)
Exhibit 23: Anticholinergic agents - Market size and forecast 2018-2023 ($ millions)
Exhibit 24: Anticholinergic agents - Year-over-year growth 2019-2023 (%)
Exhibit 25: Tricyclic antidepressants - Market size and forecast 2018-2023 ($ millions)
Exhibit 26: Tricyclic antidepressants - Year-over-year growth 2019-2023 (%)
Exhibit 27: Others - Market size and forecast 2018-2023 ($ millions)
Exhibit 28: Others - Year-over-year growth 2019-2023 (%)
Exhibit 29: Market opportunity by product
Exhibit 30: Customer landscape
Exhibit 31: Market share by geography 2018-2023 (%)
Exhibit 32: Geographic comparison
Exhibit 33: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 34: North America - Year-over-year growth 2019-2023 (%)
Exhibit 35: Top 3 countries in North America
Exhibit 36: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 37: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 38: Top 3 countries in Europe
Exhibit 39: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 40: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 41: Top 3 countries in Asia
Exhibit 42: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 43: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 44: Top 3 countries in ROW
Exhibit 45: Key leading countries
Exhibit 46: Market opportunity
Exhibit 47: Global prevalence of geriatric population
Exhibit 48: Impact of drivers and challenges
Exhibit 49: Vendor landscape
Exhibit 50: Landscape disruption
Exhibit 51: Vendors covered
Exhibit 52: Vendor classification
Exhibit 53: Market positioning of vendors
Exhibit 54: AbbVie Inc. - Vendor overview
Exhibit 55: AbbVie Inc. - Business segments
Exhibit 56: AbbVie Inc. - Organizational developments
Exhibit 57: AbbVie Inc. - Geographic focus
Exhibit 58: AbbVie Inc. - Key offerings
Exhibit 59: AbbVie Inc. - Key customers
Exhibit 60: Acorda Therapeutics Inc. - Vendor overview
Exhibit 61: Acorda Therapeutics Inc. - Business segments
Exhibit 62: Acorda Therapeutics Inc. - Organizational developments
Exhibit 63: Acorda Therapeutics Inc. - Key offerings
Exhibit 64: Acorda Therapeutics Inc. - Key customers
Exhibit 65: Biogen Inc. - Vendor overview
Exhibit 66: Biogen Inc. - Business segments
Exhibit 67: Biogen Inc. - Organizational developments
Exhibit 68: Biogen Inc. - Geographic focus
Exhibit 69: Biogen Inc. - Key offerings
Exhibit 70: Biogen Inc. - Key customers
Exhibit 71: Bristol-Myers Squibb Co. - Vendor overview
Exhibit 72: Bristol-Myers Squibb Co. - Business segments
Exhibit 73: Bristol-Myers Squibb Co. - Organizational developments
Exhibit 74: Bristol-Myers Squibb Co. - Geographic focus
Exhibit 75: Bristol-Myers Squibb Co. - Key offerings
Exhibit 76: Bristol-Myers Squibb Co. - Key customers
Exhibit 77: Merck & Co. Inc. - Vendor overview
Exhibit 78: Merck & Co. Inc. - Business segments
Exhibit 79: Merck & Co. Inc. - Organizational developments
Exhibit 80: Merck & Co. Inc. - Geographic focus
Exhibit 81: Merck & Co. Inc. - Segment focus
Exhibit 82: Merck & Co. Inc. - Key offerings
Exhibit 83: Merck & Co. Inc. - Key customers
Exhibit 84: Validation techniques employed for market sizing
Exhibit 85: Definition of market positioning of vendors
Keyplayers in Global Progressive Supranuclear Palsy Therapeutics Market 2019-2023
AbbVie Inc.Acorda Therapeutics Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Merck & Co. Inc.